For research use only. Not for therapeutic Use.
Bendazac L-Lysine is one of agents that have been introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.
| Catalog Number | I013036 |
| CAS Number | 81919-14-4 |
| Synonyms | 2-(1-benzylindazol-3-yl)oxyacetic acid;(2S)-2,6-diaminohexanoic acid |
| Molecular Formula | C22H28N4O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C16H14N2O3.C6H14N2O2/c19-15(20)11-21-16-13-8-4-5-9-14(13)18(17-16)10-12-6-2-1-3-7-12;7-4-2-1-3-5(8)6(9)10/h1-9H,10-11H2,(H,19,20);5H,1-4,7-8H2,(H,9,10)/t;5-/m.0/s1 |
| InChIKey | OCOCFNMFLNFNIA-ZSCHJXSPSA-N |
| SMILES | C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)OCC(=O)O.C(CCN)CC(C(=O)O)N |
| Reference | [1]. Yin XX, et al. Protective effects of bendazac lysine on early experimental diabetic nephropathy in rats. |
